What Is Fragment 176-191?
Fragment 176-191, a modified version derived from AOD9604, represents a small segment of human growth hormone (hGH) occasionally termed the “lipolytic fragment.” This designation stems from laboratory studies indicating its capability to amplify fat burning, notably observed in mice genetically engineered to possess substantial fat reserves. Extensively studied in animal models, Fragment 176-191 retains the fat-burning properties of hGH while circumventing certain other effects linked to its parent protein, such as elevating insulin-like growth factor-1 (IGF-1) levels, influencing carbohydrate metabolism adversely, impacting insulin sensitivity, stimulating long bone growth, and similar outcomes. The specific targeted actions of Fragment 176-191 render it valuable for investigating human fat metabolism and hold promise for potential development as anti-obesity medications in the future.

What is AOD9604?
AOD9604, derived from fragment 176-191, itself a modified smaller component of human growth hormone (HGH), was initially formulated as an anti-obesity medication, primarily owing to its lipolytic (fat burning) attributes. This peptide stands out due to its selective impact primarily centered on fat burning, exhibiting limited influence on other physiological aspects. Notably, it doesn’t seem to affect insulin-like growth factor-1 (IGF-1) or insulin levels, thus lacking association with promoting glucose intolerance or diabetes risk. Additionally, evidence suggests that AOD9604 doesn’t provoke the formation of antibodies in the body, as its structural similarity to HGH prevents the stimulation of an immune system response.